BioNTech SE (BNTX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
BNTX currently has 240M outstanding shares. with significant dilution risk as 227B authorized shares could dilute existing holders by 94408.6%. The company has not diluted shareholders through share issuances in the past 2 years, which is positive for existing holders.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Mar 10, 2025 |
20-F filing | 240.0M shares outstanding |
240M | 230B |
| Mar 20, 2024 |
20-F filing | 237.7M shares outstanding |
240M | 230B |
| Mar 27, 2023 |
20-F filing | 241.0M shares outstanding |
240M | 230B |
| Mar 30, 2022 |
20-F filing | 246.8M shares outstanding |
250M | 230B |
| Mar 30, 2021 |
20-F filing | 241521.1M shares outstanding |
240B | 0 |
| Jul 21, 2020 |
F-1 filing: The filing relates to a rights offering and an underwritten offering of ordinary shares and ADSs, with a total of up to 6,681,849 ordinary shares (including ordinary shares represented by ADSs) to be sold in the Global Offering. |
230B | 13M |
| Jul 21, 2020 |
F-1 filing: This is an F-1 filing for a global offering consisting of an underwritten offering and a rights offering of ordinary shares represented by ADSs. |
230B | 13M |
| Mar 31, 2020 |
20-F filing | 226779.7M shares outstanding |
230B | 0 |
| Feb 07, 2020 |
RW filing: This is a request to withdraw a registration statement on Form F-1, because the proposed public offering was abandoned. |
N/A | 0 |